ORIENTBIO Corrects 2026 Earnings, Net Loss Reduced 65.39% but Operating Loss Widens
Correction of fiscal year 2026 results reflecting audit, with loss before tax and net loss reduced but operating loss widened.
Operating loss increased 34.3% due to higher inventory valuation allowances, but net loss improved 65.39% to about 4.57 billion KRW due to lower non-recurring losses in prior period.
No change in outstanding shares or capital erosion, limiting direct impact on minority shareholders, but continued operating loss expansion pressures stock price.
[AI Summary]ORIENTBIO's financial statement correction shows mixed results: operating loss deepened but net loss significantly improved year-over-year. With no share issuance or capital impairment, near-term dilution risk is absent, making the company's operational turnaround the key factor for future stock performance.
KOSPI Filing Information
[Correction of Description] Change in Sales or Profit Structure of 30% or More (15% for Large Corporations)